Trial Profile
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Meningioma
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2024 Status changed from suspended to recruiting.
- 02 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 02 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.